Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab

ZUG, Switzerland I June 7, 2021 I Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today its decision not to continue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic antibody that targets CD70.

The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia (AML). Final results from Janssen's clinical studies of cusatuzumab will be presented in the future. 

Janssen will work with argenx to transition the cusatuzumab program back to argenx. Patients currently enrolled in ongoing cusatuzumab clinical trials will continue to be supported through treatment and follow-up.  

Janssen entered into the worldwide collaboration and license agreement with argenx in December 2018 to develop and commercialize cusatuzumab in AML and potential additional indications.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal and www.twitter.com/JanssenUS. Cilag GmbH International is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

SOURCE: Janssen Pharmaceutical Companies of Johnson & Johnson

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top